Biography for Erica Teichert
Erica Teichert is the associate editor of the FierceBiotech and FiercePharma publications. A San Francisco native, Erica previously interned for the Deseret News (Utah), Where Magazine (Washington, D.C.) and BYU Magazine (Utah). She has a passion for travel, ancient history and NBA basketball-especially the Cleveland Cavaliers and Utah Jazz. She is based at the FierceMarkets main office in Washington, D.C., and can be reached at email@example.com. Follow @FierceMedDev on Twitter and find her on LinkedIn.
Articles by Erica Teichert
Scientists have discovered a mutant strain of the bird flu, which has been observed in China and Vietnam, and the variant is different enough that current vaccines won't protect against it. So far,
The National Institutes of Health has awarded Emory University a $26 million grant for its work on HIV/AIDS vaccines. The university will work to develop a vaccine in the next 5 years with the help
Researchers have found that vaccinating infants against rotavirus may help protect the unvaccinated children and adults around them. In a Centers for Disease Control and Prevention study published in
Scientists at the University of California, Davis, University of Connecticut and University of Texas Medical Branch have developed two potential vaccines for the mosquito-borne Rift Valley fever.
While HPV vaccines are mainly used to protect young women from cervical cancer, the shots have also been found to prevent other types of disease, including penile cancer and genital warts in males.
The Infectious Disease Research Institute and United States Agency for International Development have reached a memorandum of understanding to develop a new malaria vaccine in partnership with the
Seattle-based TapImmune will sponsor a Mayo Clinic Phase I study of a therapeutic breast cancer vaccine, which has received FDA IND approval. Trial recruitment, which will focus on HER-2/neu positive
Scientists at St. George's, University of London, have found a way to assist the body's immune system against cancer using an old tuberculosis remedy. A vaccine created with the germ Baculillus
In an effort to combat tuberculosis, Aeras and the Oxford-Emergent Tuberculosis Consortium have announced the start of a Phase IIb trial of the MVA85A vaccine. The 1,400-person proof-of-concept study
Vaccine maker Inviragen has signed a memorandum of understanding with the nonprofit International Vaccine Institute (IVI) for further development of dengue vaccines. Currently, Inviragen has a